These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38880808)

  • 21. Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth.
    Wenger TL; Ganti S; Bull C; Lutsky E; Bennett JT; Zenner K; Jensen DM; Dmyterko V; Mercan E; Shivaram GM; Friedman SD; Bindschadler M; Drusin M; Perkins JN; Kong A; Bly RA; Dahl JP; Bonilla-Velez J; Perkins JA
    Genet Med; 2022 Nov; 24(11):2318-2328. PubMed ID: 36066547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
    Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
    J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic Activating PIK3CA Mutations Cause Venous Malformation.
    Limaye N; Kangas J; Mendola A; Godfraind C; Schlögel MJ; Helaers R; Eklund L; Boon LM; Vikkula M
    Am J Hum Genet; 2015 Dec; 97(6):914-21. PubMed ID: 26637981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatic TEK variant with intraarticular venous malformation and knee hemarthrosis treated with rapamycin.
    Adham S; Revencu N; Mestre S; Nou-Howaldt M; Vernhet-Kovacsik H; Quéré I
    Mol Genet Genomic Med; 2022 Jun; 10(6):e1931. PubMed ID: 35426265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome.
    López Gutiérrez JC; Lizarraga R; Delgado C; Martínez Urrutia MJ; Díaz M; Miguel M; Triana P
    J Pediatr Adolesc Gynecol; 2019 Dec; 32(6):648-650. PubMed ID: 31330249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four-month-old with severe PIK3CA-related overgrowth spectrum disorder successfully treated with alpelisb.
    Cossio ML; Rodríguez J; Flores JC; De Barbieri F; Flores Á; Marín J; Florin C; Cuevas F; Gutiérrez M
    Pediatr Dermatol; 2024; 41(4):714-717. PubMed ID: 38444084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffuse capillary malformation with overgrowth contains somatic PIK3CA variants.
    Goss JA; Konczyk DJ; Smits P; Sudduth CL; Bischoff J; Liang MG; Greene AK
    Clin Genet; 2020 May; 97(5):736-740. PubMed ID: 31909475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
    Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
    Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
    Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
    [No Abstract]   [Full Text] [Related]  

  • 30. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
    di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
    Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.
    Kobialka P; Sabata H; Vilalta O; Gouveia L; Angulo-Urarte A; Muixí L; Zanoncello J; Muñoz-Aznar O; Olaciregui NG; Fanlo L; Esteve-Codina A; Lavarino C; Javierre BM; Celis V; Rovira C; López-Fernández S; Baselga E; Mora J; Castillo SD; Graupera M
    EMBO Mol Med; 2022 Jul; 14(7):e15619. PubMed ID: 35695059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatic mutations in exon 17 of the TEK gene in vascular tumors and vascular malformations.
    Ye C; Pan L; Huang Y; Ye R; Han A; Li S; Li X; Wang S
    J Vasc Surg; 2011 Dec; 54(6):1760-8. PubMed ID: 21962923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repurposing alpelisib, an anti-cancer drug, for the treatment of severe TIE2-mutated venous malformations: Preliminary pharmacokinetics and pharmacodynamic data.
    Remy A; Tran TH; Dubois J; Gavra P; Lapointe C; Winikoff R; Facundo GB; Théorêt Y; Kleiber N
    Pediatr Blood Cancer; 2022 Oct; 69(10):e29897. PubMed ID: 35876545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrofacial vascular metameric syndrome is caused by somatic pathogenic variants in
    Sheppard SE; Sanders VR; Srinivasan A; Finn LS; Adams D; Elton A; Amlie-Lefond C; Nelson Z; Dmyterko V; Jensen D; Zenner K; Perkins J; Bennett JT
    Cold Spring Harb Mol Case Stud; 2021 Dec; 7(6):. PubMed ID: 34887309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive targeted next-generation sequencing in patients with slow-flow vascular malformations.
    Nozawa A; Fujino A; Yuzuriha S; Suenobu S; Kato A; Shimizu F; Aramaki-Hattori N; Kuniyeda K; Sakaguchi K; Ohnishi H; Aoki Y; Ozeki M
    J Hum Genet; 2022 Dec; 67(12):721-728. PubMed ID: 36171295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microphysiological model of PIK3CA-driven vascular malformations reveals a role of dysregulated Rac1 and mTORC1/2 in lesion formation.
    Aw WY; Cho C; Wang H; Cooper AH; Doherty EL; Rocco D; Huang SA; Kubik S; Whitworth CP; Armstrong R; Hickey AJ; Griffith B; Kutys ML; Blatt J; Polacheck WJ
    Sci Adv; 2023 Feb; 9(7):eade8939. PubMed ID: 36791204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
    Garreta Fontelles G; Pardo Pastor J; Grande Moreillo C
    Br J Clin Pharmacol; 2022 Aug; 88(8):3891-3895. PubMed ID: 35146800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Venous malformations: PIK3CA mutations guide new treatments.
    Dbouk HA
    Oncotarget; 2016 Aug; 7(31):48852-48853. PubMed ID: 27447853
    [No Abstract]   [Full Text] [Related]  

  • 39. Progressive vascular tumor in infant: A case report and literature review of PIK3CA vascular malformation.
    Medina A; Zima L; Atkinson A; Menon NM; Bhattacharjee M; Bonfante E; Sandberg DI; Greives MR; Shah M
    Childs Nerv Syst; 2024 Apr; 40(4):1005-1010. PubMed ID: 38265477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
    André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
    Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.